SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic

A Bertoletti, N Le Bert, AT Tan - Immunity, 2022 - cell.com
Since the onset of the coronavirus disease 2019 (COVID-19) pandemic, multiple severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increasing ability to …

[HTML][HTML] SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines

S Pather, SA Madhi, BJ Cowling, P Moss… - Frontiers in …, 2023 - frontiersin.org
The highly transmissible Omicron (B. 1.1. 529) variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was first detected in late 2021. Initial Omicron waves were …

[HTML][HTML] Modeling transmission of SARS-CoV-2 omicron in China

J Cai, X Deng, J Yang, K Sun, H Liu, Z Chen, C Peng… - Nature medicine, 2022 - nature.com
Having adopted a dynamic zero-COVID strategy to respond to SARS-CoV-2 variants with
higher transmissibility since August 2021, China is now considering whether, and for how …

Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling …

CKH Wong, ICH Au, KTK Lau, EHY Lau, BJ Cowling… - The Lancet, 2022 - thelancet.com
Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

[HTML][HTML] Real-world COVID-19 vaccine effectiveness against the Omicron BA. 2 variant in a SARS-CoV-2 infection-naive population

JJ Lau, SMS Cheng, K Leung, CK Lee, A Hachim… - Nature medicine, 2023 - nature.com
Abstract The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and
escape of vaccine-derived immunity. Although first-generation vaccines remain effective …

[HTML][HTML] Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on …

CKH Wong, ICH Au, KTK Lau, EHY Lau… - The Lancet Infectious …, 2022 - thelancet.com
Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …

Omicron BA. 2 breakthrough infection enhances cross-neutralization of BA. 2.12. 1 and BA. 4/BA. 5

A Muik, BG Lui, M Bacher, AK Wallisch, A Toker… - Science …, 2022 - science.org
BNT162b2-vaccinated individuals after Omicron BA. 1 breakthrough infection have strong
serum-neutralizing activity against Omicron BA. 1, BA. 2, and previous SARS-CoV-2 variants …

[HTML][HTML] Epidemiology of infections with SARS-CoV-2 Omicron BA. 2 variant, Hong Kong, January–March 2022

YM Mefsin, D Chen, HS Bond, Y Lin… - Emerging infectious …, 2022 - ncbi.nlm.nih.gov
Our analysis of data collected from multiple epidemics in Hong Kong indicated a shorter
serial interval and generation time of infections with the SARS-CoV-2 Omicron variant. The …

[HTML][HTML] COVID-19 mortality and vaccine coverage—Hong Kong special administrative region, China, January 6, 2022–March 21, 2022

DJ Smith - MMWR. Morbidity and mortality weekly report, 2022 - cdc.gov
Among persons aged≥ 60 years in Hong Kong, 49% had received≥ 2 doses of a COVID-
19 vaccine, and vaccination coverage declined with age. During January–March 2022 …

[HTML][HTML] Epidemiological characteristics and transmission dynamics of the outbreak caused by the SARS-CoV-2 Omicron variant in Shanghai, China: a descriptive …

Z Chen, X Deng, L Fang, K Sun, Y Wu… - The Lancet Regional …, 2022 - thelancet.com
Summary Background In early March 2022, a major outbreak of the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) Omicron variant spread rapidly throughout …